Impact of pharmacist participation in the patient care team on value-based health measures

Purpose To evaluate whether pharmacist engagement on the interdisciplinary team leads to improved performance on diabetes-related quality measures. Methods This was a retrospective observational study of patients seen in primary care and specialty clinics from October 2014 to October 2020. Patients were included if they had a visit with a physician, nurse practitioner, physician's assistant, or clinical pharmacist practitioner (CPP) within the study period and had a diagnosis of diabetes. The intervention group included patients with at least one visit with a CPP, while the control group consisted of patients who were exclusively managed by non-CPP providers. The primary outcome of this study was the median change in glycosylated hemoglobin (HbA(1c)) from baseline to follow-up at 3, 6, and 12 months. The secondary outcome was the probability of achieving the HbA(1c) targets of <7% and <8% at 3, 6, and 12 months. Results Patients referred to a CPP had higher HbA(1c) levels at baseline and were more likely to have concomitant hypertension (P < 0.01). Patients seen by a CPP had 0.31%, 0.41%, and 0.44% greater reductions in HbA(1c) compared to patients in the control group at 3, 6, and 12 months, respectively (P < 0.01). Patients managed by a CPP were also more likely to achieve the identified HbA(1c) targets of Conclusion Patients referred to a CPP were more complex, but had greater reductions in HbA(1c) and were more likely to achieve HbA(1c) goals included in the organization's quality measures. This study demonstrates the value of pharmacists in improving patient care and their role in supporting an organization's achievement of value-based quality measures.